Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

KLRS Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Kalaris Therapeutics IncNASDAQ: KLRS

Short-term Investments · Q1 FY2026 · quarter ended Mar 2026

Short-term investments remains negative

Q1 FY2026 short-term investments was $62.79M, compared with $0 a year earlier.

Context

  • Short-term investments amounted to 57.2% of total assets at the end of Q1 FY2026, up 57.2 pp from a year earlier.
  • Short-term investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$62.79M+215.1% QoQ
Last fiscal yearDec 2025
$19.93M— YoY
Year agoMar 2025
$0— since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
19.93M USD
Year-over-year change
—
4-year CAGR
-19.1%

Short-term Investments vs competitors

How KLRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
  • Short-term investments amounts to 57.2% of total assets for KLRS, versus a peer median of 28.7%.
KLRS Competitors
Short-term Investments for KLRS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
STROSutro Biopharma, Inc.Mar 2026$128.88M USD-9.7%-33.8%53.3%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$65.83M USD-51.4%—62.1%
KLRSKalaris Therapeutics IncMar 2026$62.79M USD——57.2%
OVIDOvid Therapeutics Inc.Mar 2026$61.46M USD+181.1%-12.4%27.2%
IMAImageneBio IncMar 2026$41.16M USD-46.7%-25.1%30.1%
IFRXInflaRx N.V.Mar 2026€24.83M EUR+33.7%-22.6%50.7%
CNTBConnect Biopharma Holdings LimitedDec 2025$6M USD-61.2%-56.6%10.7%
STTKShattuck Labs, Inc.Mar 2026$0 USD—-40.6%0.0%
CNTXContext Therapeutics Inc.Mar 2026$0 USD——0.0%
Peer median (excluding KLRS) —-28.2%-29.4%28.7%

Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents201.66M3.06M3.17M118.29M98.05M
Short-term Investments46.46M00019.93M
Net Receivables50K0000
Inventory00000
Other Current Assets5.18M3K17K257K78K
Total Current Assets253.35M3.9M3.33M118.55M118.81M
Property, Plant & Equipment (Net)31.29M0001.48M
Goodwill00000
Intangible Assets00000
Long-term Investments852K000499K
Tax Assets00000
Other Non-current Assets1.1M000953K
Total Non-current Assets33.25M0002.93M
Total Assets286.59M3.9M3.33M118.55M121.74M
Account Payables8.36M2.76M2.36M247K1.28M
Short-term Debt6.59M000316K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities15.03M296K540K1.96M6.52M
Total Current Liabilities37.85M5.69M3.94M5.24M9.71M
Long-term Debt03.25M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities025.23M44.41M032.08M
Total Non-current Liabilities23.48M28.48M44.41M033.21M
Total Liabilities61.33M34.17M48.35M5.24M42.92M
Common Stock7K0002K
Retained Earnings(297.07M)(32.7M)(47.39M)(714.96M)(160M)
Accumulated OCI(155K)00(135K)6K
Other Stockholders Equity00000
Minority Interest00000
Total Equity225.27M(30.27M)(45.02M)113.31M78.81M
Total Debt30.07M3.25M001.45M
Net Debt(171.6M)194K(3.17M)(118.29M)(96.61M)

Kalaris Therapeutics Inc

NASDAQ:KLRS

Intrinsic Alpha fair value

Locked

Current Price

$2.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.